Pfizer and Flynn accused of charging NHS ‘unfairly high’ prices

Pfizer and Flynn have been accused by the Competition and Markets Authority of abusing their dominant positions to overcharge the NHS for anti-epilepsy medication (PA)

Drugs firms Pfizer and Flynn have been accused by the UK’s competition watchdog of abusing their dominant positions to overcharge the NHS for anti-epilepsy medication in sky-high “overnight” price hikes.

The Competition and Markets Authority (CMA) said it has provisionally found that Flynn and Covid-19 vaccine maker Pfizer broke competition law by charging “unfairly high” prices for phenytoin sodium capsules – sending the cost of the treatment soaring by up to 2,600%.